Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
N
092730
vs
K
KOSPI 200
Over the past 12 months, NeoPharm Co Ltd has underperformed KOSPI 200, delivering a return of +31% compared to KOSPI 200's +56% growth.
Stocks Performance
092730 vs KOSPI 200
Performance Gap
092730 vs KOSPI 200
Performance By Year
092730 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
NeoPharm Co Ltd
Glance View
NeoPharm Co Ltd is a South Korean healthcare company that makes and sells medicines and skin-care products. Its product line is centered on prescription and over-the-counter drugs, along with items used for skin health, wound care, and daily treatment needs. The company earns money mainly by selling these products through healthcare and retail channels. Its main customers are hospitals, clinics, pharmacies, and consumers who buy skin and care products for home use. Unlike a pure drug developer that only licenses molecules, NeoPharm also participates in product development, manufacturing, and commercial sales, which gives it a more direct role in reaching end users. The company’s business model depends on steady demand for common treatment products and branded specialty items rather than one-off projects. That makes it more like a focused healthcare product maker than a broad medical conglomerate, with value coming from formulas, brands, and distribution relationships that help its products stay on shelves and in medical settings.